176 related articles for article (PubMed ID: 21073062)
61. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
[TBL] [Abstract][Full Text] [Related]
62. Comparison of two recombinant hepatitis B vaccines and their interchangeability in Argentine infants.
Tregnaghi M; Ussher J; Baudagna AM; Calvari M; Graña G
Rev Panam Salud Publica; 2004 Jan; 15(1):35-40. PubMed ID: 14987456
[TBL] [Abstract][Full Text] [Related]
63. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.
Cooper CL; Davis HL; Angel JB; Morris ML; Elfer SM; Seguin I; Krieg AM; Cameron DW
AIDS; 2005 Sep; 19(14):1473-9. PubMed ID: 16135900
[TBL] [Abstract][Full Text] [Related]
64. Immunogenicity of two recombinant hepatitis B vaccines in older individuals.
Treadwell TL; Keeffe EB; Lake J; Read A; Friedman LS; Goldman IS; Howell CD; DeMedina M; Schiff ER; Jensen DM
Am J Med; 1993 Dec; 95(6):584-8. PubMed ID: 8259774
[TBL] [Abstract][Full Text] [Related]
65. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination.
Cossio-Gil Y; Martínez-Gómez X; Campins-Martí M; Rodrigo-Pendás JÁ; Borruel-Sainz N; Rodríguez-Frías F; Casellas-Jordà F
J Gastroenterol Hepatol; 2015 Jan; 30(1):92-8. PubMed ID: 25160690
[TBL] [Abstract][Full Text] [Related]
66. The safety and immunogenicity of two hepatitis B vaccine formulations (thiomersal-free and thiomersal-containing) in healthy vietnamese infants: a phase III, prospective, single-blinded, randomized, controlled trial.
Hieu NT; Sarnecki M; Tolboom J
Pediatr Infect Dis J; 2015 Jan; 34(1):79-83. PubMed ID: 25036048
[TBL] [Abstract][Full Text] [Related]
67. Immunogenicity of two doses of yeast recombinant hepatitis B vaccine in healthy older adults.
Gellin BG; Greenberg RN; Hart RH; Bertino JS; Stein DH; Deloria MA; Clements-Mann ML
J Infect Dis; 1997 Jun; 175(6):1494-7. PubMed ID: 9180192
[TBL] [Abstract][Full Text] [Related]
68. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine.
Shapira MY; Zeira E; Adler R; Shouval D
J Hepatol; 2001 Jan; 34(1):123-7. PubMed ID: 11211888
[TBL] [Abstract][Full Text] [Related]
69. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.
Cooper CL; Davis HL; Morris ML; Efler SM; Adhami MA; Krieg AM; Cameron DW; Heathcote J
J Clin Immunol; 2004 Nov; 24(6):693-701. PubMed ID: 15622454
[TBL] [Abstract][Full Text] [Related]
70. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines.
Leroux-Roels G; Desombere I; Cobbaut L; Petit MA; Desmons P; Hauser P; Delem A; De Grave D; Safary A
Vaccine; 1997 Nov; 15(16):1732-6. PubMed ID: 9364675
[TBL] [Abstract][Full Text] [Related]
71. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report.
Hourvitz A; Mosseri R; Solomon A; Yehezkelli Y; Atsmon J; Danon YL; Koren R; Shouval D
J Viral Hepat; 1996 Jan; 3(1):37-42. PubMed ID: 8736239
[TBL] [Abstract][Full Text] [Related]
72. Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--third generation pre-S/S vaccines overcome non-response.
Zuckerman JN
J Viral Hepat; 1998 Nov; 5 Suppl 2():13-5. PubMed ID: 9857355
[TBL] [Abstract][Full Text] [Related]
73. A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine.
Young MD; Rosenthal MH; Dickson B; Du W; Maddrey WC
Vaccine; 2001 May; 19(25-26):3437-43. PubMed ID: 11348708
[TBL] [Abstract][Full Text] [Related]
74. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents.
Leroux-Roels G; Abraham B; Fourneau M; De Clercq N; Safary A
Vaccine; 2000 Nov; 19(7-8):937-42. PubMed ID: 11115719
[TBL] [Abstract][Full Text] [Related]
75. Immunogenicity of a recombinant hepatitis B vaccine (Euvax-B) in haemodialysis patients and staff.
Tele SA; Martins RM; Lopes CL; dos Santos Carneiro MA; Souza KP; Yoshida CF
Eur J Epidemiol; 2001; 17(2):145-9. PubMed ID: 11599688
[TBL] [Abstract][Full Text] [Related]
76. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults.
Joines RW; Blatter M; Abraham B; Xie F; De Clercq N; Baine Y; Reisinger KS; Kuhnen A; Parenti DL
Vaccine; 2001 Sep; 19(32):4710-9. PubMed ID: 11535321
[TBL] [Abstract][Full Text] [Related]
77. Comparison study of the immunogenicity and safety of 5- and 10-microgram dosages of a recombinant hepatitis B vaccine in healthy infants.
Goldfarb J; Medendorp SV; Garcia H; Nagamori K; Rathfon H; Krause D
Pediatr Infect Dis J; 1996 Sep; 15(9):764-7. PubMed ID: 8878217
[TBL] [Abstract][Full Text] [Related]
78. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B
Elhanan E; Boaz M; Schwartz I; Schwartz D; Chernin G; Soetendorp H; Gal Oz A; Agbaria A; Weinstein T
Clin Exp Nephrol; 2018 Feb; 22(1):151-158. PubMed ID: 28456864
[TBL] [Abstract][Full Text] [Related]
79. Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders.
Goldwater PN
Vaccine; 1994 Apr; 12(5):410-4. PubMed ID: 8023548
[TBL] [Abstract][Full Text] [Related]
80. Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule.
ul-Haq N; Hasnain SS; Umar M; Abbas Z; Valenzuela-Silva C; Lopez-Saura P
Vaccine; 2003 Jul; 21(23):3179-85. PubMed ID: 12804846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
